Trial Profile
A Phase II Trial of BAY 43-9006 (NSC-724772) in Patients With Platinum-Treated Extensive Stage Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 01 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 May 2008 Results to be presented at the Annual Meeting of the American Society of Clinical Oncology 2008.
- 22 Oct 2005 New trial record.